Adoption of the 21-gene recurrence score assay on receipt of chemotherapy was strongly population dependent.
Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in heavily pretreated and refractory multiple myeloma.
Induction chemotherapy administered before surgery with curative intent did not improve outcomes in locoregionally advanced oral cavity cancer.
In a Scottish population, about 5% of patients who were diagnosed with solid cancers experienced critical illness.
Combination of chemotherapy with dasatinib is effective in achieving long-term remission for in Ph+ acute lymphoblastic leukemia (ALL).
Patupilone demonstrated activity in heavily pretreated patients with recurrent brain metastases from non-small cell lung cancer (NSCLC).
Approximately 277,000 colorectal cancer (CRC) cases and 203,000 CRC deaths can be averted if screening and prevalence to 80% is reached.
An experimental blood test may one day detect the return of early-stage breast cancer months before it is revealed.
Excision repair cross-complementing group 1 (ERCC1) genotype may identify favorable prognosis for subgroup of nasopharyngeal carcinoma (NPC).
A majority of women who receive false positives on mammography experience distress and anxiety.
Increased travel burden is associated with a decreased likelihood of receiving adjuvant chemotherapy for treatment of colon cancer.
Pazopanib-induced hypertension did not correlate with outcome in pazopanib-treated soft tissue sarcoma patients.
A single infusion of ibandronate had outcomes similar to a single dose of radiotherapy for metastatic bone pain in prostate cancer.
There is no association between common genetic variants and prostate cancer survival.
Acupuncture appears to be more efficacious than oral medication for treating hot flashes in breast cancer survivors.
Electronic trigger-based interventions appear to be effective in reducing time to diagnostic evaluation of colorectal and prostate cancers.
Lenalidomide plus rituximab is more active than lenalidomide alone in patients with recurrent follicular lymphoma with similar toxicity.
The addition of trebananib to sunitinib may provide a benefit to patients with metastatic clear cell renal cell carcinoma.
Regorafenib for third-line management of metastatic colorectal cancer may provide minimal incremental benefit at high incremental cost.
Live and recorded perioperative music therapy reduces anxiety in patients undergoing surgery for potential or known breast cancer.
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- FDA Grants Breakthrough Therapy Designation to Cabozantinib for Renal Cell Carcinoma
- In Fit Patients With NSCLC, Erlotinib Not Recommended
- Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity
- New Hormonal Agents for Prostate Cancer May Increase Risk of Cardiotoxicity
- Dasatinib-induced Pulmonary Hypertension in Patients With Leukemia
- Molecular Profiles Can be Used for Early Detection for Aggressive Prostate Cancer
- Thyroid Carcinoma Treatment Regimens
- Combining Aromatase Inhibitors, Bisphosphonates May Benefit Women With Breast Cancer
- Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology
- A Decade of Dramatic Change in the Treatment of Prostate Cancer
- Immunotherapy Combinations for Renal Cell Carcinoma Offer Promise, Challenges
- Association of 21-Gene Recurrence Score Assay, Chemo in Early-stage Breast Cancer
- In Heavily Pretreated Refractory Myeloma, Daratumumab May Be Safe, Effective
- In Locoregionally Advanced Oral Cavity Cancer, Preop Induction Chemo May Not Improve Outcomes
- Patients With Solid Tumors Face Risk for Critical Illness
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|